SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

PRAX-050

PRAX·Praxis Precision Medicines, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Not stated
Time to market
Not stated
Why 2/10
No upcoming catalyst is scheduled for PRAX-050 in the next ~12 months; the drug is not mentioned in any FDA catalysts, clinical trials, press releases, or investor-day materials found across web and SecBot data sources, indicating it is likely a very early-stage or discontinued pipeline candidate with no near-term binary event.
Actionable Insight NEUTRAL

PRAX-050 does not appear in any public pipeline, trial, or regulatory record for Praxis Precision Medicines. The company's near-term value is driven entirely by relutrigine (PDUFA December 27, 2026) and ulixacaltamide (PDUFA January 29, 2027). Investors should monitor those two catalysts rather than PRAX-050.

Price Chart

Loading chart...

Executive Summary

PRAX-050 is a development code assigned by Praxis Precision Medicines, but extensive web research and database searches across FDA records, clinical trials, SEC filings, press releases, and the company's November 2026 investor day found zero references to this specific compound. It is not listed among Praxis's known pipeline assets (relutrigine, ulixacaltamide, elsunersen, vormatrigine) and has no disclosed mechanism, clinical data, or regulatory status. The drug appears to be either a very early preclinical candidate that was never advanced or a code that has been discontinued.

How It Works

Unknown. No mechanism of action has been publicly disclosed for PRAX-050.

Trial Status

No clinical trial records, FDA filings, or pipeline references to PRAX-050 were found in any public or SecBot database. The drug does not appear in ClinicalTrials.gov, FDA catalyst records, SEC filings, press releases, or the company's November 2026 investor-day materials.

The Two-Sided Case

▲ Bull Case0
▼ Bear Case3
PRAX-050 has zero public presence: no clinical trials, no FDA filings, no press releases, and no mention in the company's November 2026 investor-day pipeline update.
The drug is not among Praxis's known pipeline candidates (relutrigine, ulixacaltamide, elsunersen, vormatrigine), suggesting it may have been deprioritized or discontinued.
With no disclosed mechanism, phase, or development timeline, there is no basis to assign any value to PRAX-050 as an investable asset.

Upcoming Catalysts

  • None identified for PRAX-050 specifically. Praxis's overall catalysts are relutrigine PDUFA on December 27, 2026, and ulixacaltamide PDUFA on January 29, 2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report

Sources · 7

Hover a chip for the title
1 tipranks.com2 marketscreener.com3 fiercebiotech.com4 ad-hoc-news.de5 seekingalpha.com6 theglobeandmail.com7 sec.gov